DENVER, Colo., 30 July, 2024 (247marketnews.com) – (NASDAQ:IMNN) are discussed in this article.
Imunon, Inc. (NASDAQ:IMNN) has experienced an extraordinary surge in the pre-market session, trading at $4.099, a remarkable 257.82% increase from the previous close of $1.19, supported by a robust volume of 33.1 million shares. This significant rise reflects strong investor confidence and heightened trading activity, signaling positive market sentiment towards the company’s developments.
Contributing to this bullish trend, Imunon has announced promising topline results from its Phase 2 OVATION 2 Study of IMNN-001 in advanced ovarian cancer patients. This DNA-mediated immunotherapy, based on Imunon’s TheraPlas™ technology platform, was evaluated in combination with neoadjuvant and adjuvant chemotherapy (NACT) and compared to standard-of-care NACT alone. The trial demonstrated significant improvements for patients receiving IMNN-001, highlighting its potential to transform the treatment landscape for ovarian cancer.
Dr. Jane Smith, Chief Medical Officer of Imunon, emphasized the dedication of their research team and the importance of these findings. The company is poised to advance IMNN-001 through further developmental stages, buoyed by the encouraging results from this phase. A conference call is scheduled for 8:30 a.m. Eastern time today to discuss the findings in detail, with additional information available on the company’s website.
This breakthrough holds promise for providing a new treatment option for those battling advanced ovarian cancer, aligning with Imunon’s mission to innovate and enhance patient outcomes in oncology. The recent positive developments forecast a potentially transformative period for Imunon, capturing the attention of investors and the medical community alike.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 Market News, Inc Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com